EGFR and head and neck squamous cell carcinoma: Our Phase I study of intratumoral delivery of EGFR antisense DNA in 17 patients with advanced, refractory SCCHN was associated with no grade 3 or 4 or dose-limiting toxicities and a clinical response rate (complete response and partial response by modified RECIST criteria) of 29% [9].